Related Experiment Videos
Combination chemotherapy for primitive neuroectodermal and other malignant brain tumours
M N Gaze1, D B Smith, R P Rampling
1Beatson Oncology Centre, Western Infirmary, Glasgow, UK.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|January 1, 1994
Summary
This study assessed a chemotherapy regimen for brain tumors, finding a 70% response rate but short-lived benefits. Further evaluation is needed for this treatment option in pediatric and adult patients.
Area of Science:
- Pediatric Oncology
- Neuro-Oncology
- Medical Oncology
Background:
- Malignant brain tumors like medulloblastoma and primitive neuroectodermal tumors (PNET) present significant treatment challenges, particularly in pediatric populations.
- Evaluating novel chemotherapy regimens is crucial for improving outcomes in patients with recurrent or poor-prognosis brain tumors.
Purpose of the Study:
- To assess the toxicity and efficacy of an alternating chemotherapy schedule (vincristine/cyclophosphamide with carboplatin/etoposide) in patients with malignant brain tumors.
- To determine the response rate, duration of response, and toxicity profile of this regimen in adults and children.
Main Methods:
- A total of 15 patients (11 children, 4 adults) with medulloblastoma, supratentorial PNET, or other malignant brain tumors received the alternating chemotherapy schedule.
- Treatment indications included palliation of recurrent disease, adjuvant therapy, or delaying radiotherapy in very young children.
- Toxicity was monitored, and treatment response was assessed in 10 assessable patients.
Main Results:
- The chemotherapy regimen was generally well tolerated, with myelosuppression as the primary toxicity.
- An overall response rate of 70% was observed (6 complete responders, 1 partial responder) among 10 assessable patients.
- Responses were often short-lived, with relapses occurring during or shortly after treatment, necessitating further interventions like radiotherapy.
Conclusions:
- The assessed alternating chemotherapy schedule demonstrates a notable response rate in malignant brain tumors but offers limited duration of benefit.
- This regimen warrants further investigation and comparison against established, potentially more toxic, treatment protocols.
- The findings suggest a potential role for this schedule, particularly in specific patient subgroups or as part of a multimodal treatment strategy.